NYU'S Permutter Cancer Center & the Technion-Israel Institute of Technology launched a global cancer research initiative. I
n their first joint collaboration, NYU Langone and Technion researchers will test the ability of a nanotechnology based on stem cell "nanoghosts" to deliver to the brain a promising treatment for metastatic melanoma; skin cancer that has spread or metastasized, and is often incurable.
Professor Marcelle Machluf,
|Nanoghosts: A naturally targeted drug and gene delivery system
who visited the Phoenix/Scottsdale area just last November, explains that their "
studies should provide important information on nanoghosts' general value as drug and gene carriers to the brain, and create potential for new treatment approaches against brain tumors and metastases." Professor Machluf, PhD, is the head of the Laboratory for Cancer Drug Delivery & Cell Based Technologies at the Technion, and is inventor of the nanoghost with her colleagues there.
"The difficulty of delivering agents to the brain represents a major impediment to improving outcomes in patients suffering from brain tumors. Our state-of-the-art nanovehicle promises safer, simpler and more clinically relevant treatments than existing vehicles, which are comprised of polymers or synthetic vesicles which largely lack the ability to enter the brain and to target evolving and changing pathologies," stated Professor Machluf.